KI researcher Tore Curstedt nominated for EPO Lifetime Achievement Award

Published 2016-05-10 12:34. Updated 2016-05-11 15:18Denna sida på svenska


Docent Tore Curstedt at Karolinska Institutet’s Department of Molecular Medicine and Surgery has been nominated by the European Patent Office (EPO) for a Lifetime Achievement Award at the 2016 European Inventor Award ceremony for his work with Curosurf.

Tore Curstedt is nominated for the work he and his colleague Bengt Robertsson have done on their innovative treatment for preterm babies with respiratory distress syndrome (RDS). The method, which was introduced in 1989, has now been administered to over three million infants.

The drug developed by Dr Curstedt is marketed under the name Curosurf and is used in 80 countries, where it is estimated to have saved the lives of over half a million preterm babies.

The nominations deadline is 31 May, and the prize ceremony will be held in Lisbon on 9 June 2016.

Read more about the prize and Tore Curstedt’s nomination on the EPO website.